Amiodarone is highly effective for managing cardiac arrhythmias, but its long-term use is limited by a broad profile of adverse effects. Because the drug is highly lipid-soluble (fat-soluble) and contains significant amounts of iodine, it accumulates in body tissues over time. Consequently, many of its toxicities are cumulative and depend on the total dose taken.
Pulmonary Toxicity
Amiodarone-induced pulmonary toxicity is the most severe and potentially fatal complication, affecting approximately 1% to 5% of patients.
- Pathology: It most commonly presents as interstitial pneumonitis (inflammation of the lung tissue) or organizing pneumonia, which can progress to irreversible pulmonary fibrosis (scarring) if undetected.
- Symptoms: Patients typically experience an insidious onset of a dry, non-productive cough, shortness of breath, and occasionally a low-grade fever.
- Monitoring: Baseline chest X-rays and pulmonary function tests (specifically checking gas diffusion capacity) are required before starting the drug, with annual imaging thereafter.
Thyroid Dysfunction
Because amiodarone structurally resembles thyroxine and consists of about 37% iodine by weight, it profoundly impacts thyroid hormone metabolism.
- Hypothyroidism (underactive thyroid): This is the most common adverse effect, occurring in up to 20% of patients. It causes fatigue, weight gain, and cold intolerance. It can usually be managed by adding a thyroid hormone replacement (like levothyroxine) without needing to stop the amiodarone.
- Hyperthyroidism (overactive thyroid): Occurring in 1% to 2% of patients, this is more difficult to manage and can dangerously exacerbate underlying heart conditions by causing rapid heart rates and weight loss. It often requires discontinuing the drug.
- Monitoring: Thyroid function tests (TSH and free T4/T3) should be checked at baseline and every 3 to 6 months during therapy.
Ocular Effects
- Corneal Microdeposits: Tiny deposits accumulate on the surface of the eye in 70% to 100% of patients on long-term therapy. While practically universal, they are usually harmless and do not impair vision, though some patients report seeing visual halos around lights at night.
- Optic Neuropathy: A rare (less than 1%) but critical complication involving inflammation or damage to the optic nerve.
Hepatic Toxicity
- Asymptomatic Transaminitis: Up to 30% of patients will experience a mild, asymptomatic elevation in liver enzymes.
- Hepatitis and Cirrhosis: In rare cases (1% to 3%), the drug causes severe liver damage, leading to hepatitis or cirrhosis.
- Monitoring: Liver function tests should be evaluated before treatment and every 6 months. If enzymes rise to three times the upper limit of normal, the dose is typically reduced or stopped.
Dermatologic Reactions
- Photosensitivity: The skin becomes hypersensitive to UV light, making patients highly susceptible to severe sunburns. Daily use of broad-spectrum sunscreen and protective clothing is recommended.
- Ceruloderma (Blue-Gray Skin): With prolonged, high-dose use, the skin can take on a distinct blue-gray discoloration, particularly in sun-exposed areas like the face, neck, and hands. This effect slowly fades over several months once the medication is stopped.
Neurologic and Cardiac
- Neurologic: Chronic use can lead to peripheral neuropathy (numbness, tingling, or weakness in the extremities), tremors, poor coordination, and sleep disturbances, including vivid nightmares.
- Cardiac: While amiodarone suppresses arrhythmias, its mechanism of action inherently prolongs the QT interval (the time it takes for the heart to recharge electrically between beats) and slows the heart rate (bradycardia). However, its risk of triggering new, dangerous arrhythmias like Torsades de pointes is notably lower than that of other antiarrhythmics in its class.